We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

India is to test an AIDS vaccine targeted at its most prevalent strain of HIV, known as subtype C. Safety trials of the vaccine are expected to begin later this year.

It is the first time that a vaccine trial has been carried out in India, which is second only to South Africa as the country hardest hit by AIDS. In the past, India had rejected plans to test imported vaccines, as they targeted subtype B, which is prevalent in America and Europe.

Some AIDS groups have attacked the plan for the safety trial, which has yet to be approved by regulators. But others argue that the vaccine candidate has a greater chance of success than older vaccines.

Link to full news story in Nature

Reference: Nature 427, 185 (2004)

Related topics